Galectin Therapeutics Inc ARS, filed Oct 13, 2026
Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc. reported that belapectin 2mg/kg reduced esophageal varices by 49.3% in NAVIGATE’s per-protocol population (p-value<0.05) and by 68.1% among analyzed U.S. patients (p=0.02). AI summary
ARS
2026-10-13
For: 2025-12-31
View Original
Added on
October 28, 2026